Results from a 12-month, open-label safety study in patients with migraine1

In a 12-month, open-label safety study of patients with episodic or chronic migraine with 4 or more MHDs per month1


  1. Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0137.
  3. Data on File. Lilly USA, LLC. DOF-GZ-US-0139.
  4. Data on File. Lilly USA, LLC. DOF-GZ-US-0140.
  5. Data on File. Lilly USA, LLC. DOF-GZ-US-0136.
  6. Data on File. Lilly USA, LLC. DOF-GZ-US-0154.
  7. Ford JH, Foster SA, Stauffer VL, et al. Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Prefer Adherence. 2018;12:2413-2424.
  8. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.


Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.



Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache